• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
XU Fang, NIE Da-qing, CHEN Wen-li, LI Li. Efficacy comparison of rosuvastatin vs simvastatin on blood lipid and microinflammatory state in the maintenance hemodialysis patients[J]. Journal of Clinical Nephrology, 2017, 17(8): 471-476. DOI: 10.3969/j.issn.1671-2390.2017.08.005
Citation: XU Fang, NIE Da-qing, CHEN Wen-li, LI Li. Efficacy comparison of rosuvastatin vs simvastatin on blood lipid and microinflammatory state in the maintenance hemodialysis patients[J]. Journal of Clinical Nephrology, 2017, 17(8): 471-476. DOI: 10.3969/j.issn.1671-2390.2017.08.005

Efficacy comparison of rosuvastatin vs simvastatin on blood lipid and microinflammatory state in the maintenance hemodialysis patients

More Information
  • Received Date: December 14, 2015
  • Rev Recd Date: November 04, 2016
  • Available Online: May 11, 2023
  • Published Date: August 27, 2017
  • Objective To compared the efficacy of rosuvastatin vs simvastatin on blood lipid and microinflammatory state in maintenance hemodialysis (MHD) patients. Methods Seventy-eight MHD patients were enrolled between Feb. 2015 to Mar. 2016, and divided into two groups:rosuvastatin group and simvastatin group. Rosuvastatin group was treated with high flux hemodialysis therapy and rosuvastatin (10 mg, once every for 6 months). Simvastatin group was given high flux hemodialysis therapy and simvastatin (20 mg, once every day for 6 months). The general information, microinflammatory index and serum lipids were compared between two groups. Results There was no significant difference between two groups in terms of age, time of hemodialysis, BMI, Hb, MQSGA score and primary diseases. As compared with before therapy, hs-CRP, TNF-α, IL-6, TC, TG and LDL-C were significantly decreased in rosuvastatin group after treatment for 6 months. The levels of hs-CRP, IL-6 and TNF-(in rosuvastatin group were significantly lower than those in simvastatin group after treatment for 6 months[(2.25±1.21) vs (3.34±2.02), P=0.004; (7.28±3.68) vs (10.17±3.69), P<0.001; (2.14±0.86) vs (5.24±1.18), P<0.001, respectively]. The level of HDL-C was significantly increased in these two groups after treatment for 6 months as compared with that before treatment. However, there was no significant difference between these two groups in terms of HDL-C after treatment for 6 months. Conclusions Rosuvastatin is better than simvastatin in the treatment of MHD patients.
  • [1]
    Ko GJ, Lee YM, Lee EJ, et al. The association of Klotho gene polymorphism with the mortality of patients on maintenance dialysis[J]. Clinical nephrology, 2013, 80(4):263-269.
    [2]
    陈雄辉, 李震生, 吴培根, 等. 高, 低通量血液透析及联机血液透析滤过清除溶质的效果比较[J]. 中华肾脏病杂志, 2006, 22(3):158-160.
    [3]
    Chiu YW, Jiwakanon S, Lukowsky L, et al. An update on the comparisons of mortality outcomes of hemodialysis and peritoneal dialysis patients[J]. Seminars in Nephrology, 2011, 31(2):152-158.
    [4]
    Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure[J]. Kidney Int, 1999, 55(5):1899-1911.
    [5]
    Davenport A. The role of dialyzer membrane flux in bio-incompatibility[J]. Hemodialysis International, 2008, 12(Supplement s2):S29-S33.
    [6]
    易晔, 卢远航, 冀倩倩. 高通量血液透析对糖尿病肾病透析患者氧化应激及微炎症状态的影响[J]. 重庆医学, 2015, 19:2667-2669.
    [7]
    李开龙, 熊昆林, 李柱宏, 等. 阿托伐他汀对维持性血液透析患者心血管的保护作用[J]. 中国动脉硬化杂志, 2013, 21(1):57-62.
    [8]
    刘吉国, 颜俊锋, 刘春, 等. 氟伐他汀对糖尿病肾病维持性透析患者微炎症状态的影响[J]. 实用医学杂志, 2011, 27(1):106-107.
    [9]
    Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients[J]. Am Soc Nephrol, 2002, 1(13 suppl 1):S28-S36.
    [10]
    Ren H, Zhou X, Luan Z, et al. The relationship between carotid atherosclerosis, inflammatory cytokines, and oxidative stress in middle-aged and elderly hemodialysis patients[J]. International journal of nephrology, 2013, 2013(3):835465.
    [11]
    Kajitani N, Shikata K, Nakamura A. Microinflammation is a common risk factor for progression of nephropathy and atherosclerosis in Japanese patients with type 2 diabetes[J]. Diabetes research and clinical practice, 2010, 88(2):171-176.
    [12]
    Macías Núñez JF, Ghais Z, Bustamante J, et al. Evaluation of oxidant-antioxidant balance in patients on maintenance haemodialysis:a comparative study of dialyzers membranes[J]. Nephron Clinical Practice, 2009, 114(1):c67-c73.
    [13]
    李述真, 刘法芹. 不同血液透析方法对老年维持性血液透析患者体内微炎症和营养不良状态的影响[J]. 中国老年学, 2014, 21:6070-6072.
    [14]
    张丽春. 瑞舒伐他汀的临床应用[J]. 世界中西医结合杂志, 2009, 4(7):526-527.
    [15]
    罗俊, 李珂, 燕纯伯. 他汀类药物临床试验及应用最新进展[J]. 心血管病学进展, 2005, 26(1):32-35.
    [16]
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J]. Jama, 2006, 295(13):1556-1565.
    [17]
    Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease:pathogenesis and influence on outcomes[J]. Inflammation & Allergy-Drug Targets, 2009, 8(5):369-382.
    [18]
    Ballantyne CM, Pitt B, Loscalzo J, et al. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin[LUNAR] Trial)[J]. The American journal of cardiology, 2013, 111(4):506-509.
    [19]
    Tian J, Hou X, Hu L, et al. Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients[J]. Renal Failure, 2017, 39(1):153-158.
    [20]
    Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis[J]. New England Journal of Medicine, 2009, 360(14):1395-1407.

Catalog

    Article views (22) PDF downloads (284) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return